BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30473361)

  • 61. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2.
    Sun Z; Zhang S; Chan JY; Zhang DD
    Mol Cell Biol; 2007 Sep; 27(18):6334-49. PubMed ID: 17636022
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer.
    Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L
    J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Keap1-Nrf2 system and diabetes mellitus.
    Uruno A; Yagishita Y; Yamamoto M
    Arch Biochem Biophys; 2015 Jan; 566():76-84. PubMed ID: 25528168
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity.
    Lu MC; Zhang X; Wu F; Tan SJ; Zhao J; You QD; Jiang ZY
    J Med Chem; 2019 Jul; 62(14):6796-6813. PubMed ID: 31283229
    [TBL] [Abstract][Full Text] [Related]  

  • 65. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
    Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
    Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Screening of phytochemicals against Keap1- NRF2 interaction to reactivate NRF2 Functioning: Pharmacoinformatics based approach.
    Akmal A; Javaid A; Hussain R; Kanwal A; Zubair M; Ashfaq UA
    Pak J Pharm Sci; 2019 Nov; 32(6(Supplementary)):2823-2828. PubMed ID: 32024620
    [TBL] [Abstract][Full Text] [Related]  

  • 67. p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex.
    Tao S; Liu P; Luo G; Rojo de la Vega M; Chen H; Wu T; Tillotson J; Chapman E; Zhang DD
    Mol Cell Biol; 2017 Apr; 37(8):. PubMed ID: 28115426
    [TBL] [Abstract][Full Text] [Related]  

  • 68. WDR23 regulates NRF2 independently of KEAP1.
    Lo JY; Spatola BN; Curran SP
    PLoS Genet; 2017 Apr; 13(4):e1006762. PubMed ID: 28453520
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of deficiency of Kelch-like ECH-associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis.
    Sakai E; Morita M; Ohuchi M; Kido MA; Fukuma Y; Nishishita K; Okamoto K; Itoh K; Yamamoto M; Tsukuba T
    FASEB J; 2017 Sep; 31(9):4011-4022. PubMed ID: 28515152
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
    Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
    J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification of novel indole derivatives acting as inhibitors of the Keap1-Nrf2 interaction.
    Cosimelli B; Greco G; Laneri S; Novellino E; Sacchi A; Amendola G; Cosconati S; Bortolozzi R; Viola G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1152-1157. PubMed ID: 31179771
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury.
    Zhang L; Xu L; Chen H; Zhang W; Xing C; Qu Z; Yu J; Zhuang C
    Eur J Med Chem; 2021 Oct; 222():113599. PubMed ID: 34119834
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
    Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
    Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
    Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
    Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
    Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
    Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
    Zhang B; Ma Z; Tan B; Lin N
    Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
    Bello M; Morales-González JA
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
    Abed DA; Lee S; Hu L
    Bioorg Med Chem; 2020 Mar; 28(6):115343. PubMed ID: 32046917
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The natural compound 2,3,5,4'-tetrahydroxystilbene-2-O-β-d glucoside protects against adriamycin-induced nephropathy through activating the Nrf2-Keap1 antioxidant pathway.
    Lin EY; Bayarsengee U; Wang CC; Chiang YH; Cheng CW
    Environ Toxicol; 2018 Jan; 33(1):72-82. PubMed ID: 29064158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.